Scientists at The Hospital for Sick Children (SickKids) have identified a key gene that could lead to next-generation treatments for medulloblastoma, the most common malignant brain tumor in children.

It is a recessive X-linked disease, which means mothers have a 50 per cent chance of passing it to their sons. It is rare and ...

Haliza Md Kasim’s eyes widened. Despite having gone through this before with her first son, Yusof, and despite the doctors ...

K filing with the Securities and Exchange Commission (SEC) that the company has established a Collaboration and License Agreement with Nippon Shinyaku Co., Ltd. This collaboration focuses on the ...

REGENXBIO's partnership with Nippon Shinyaku provides $110M upfront, ensuring a cash runway for gene therapy programs in MPS ...

Researchers have described the neurodegeneration that occurs in the nervous system of the bowel in Batten disease, a rare and fatal genetic condition. In their latest study, a team showed that gene ...

The US biotech aims to bring its antibody-based therapies to human trials later in the year and to develop new candidate ...

As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval ...

Researchers at Washington University School of Medicine in St. Louis have described the neurodegeneration that occurs in the ...

Regenxbio will receive $110m upfront from Nippon Shinyaku and is eligible to get up to $700m in development, regulatory, and ...

REGENXBIO & Nippon Shinyaku enter exclusive partnership to develop and commercialize RGX-121 and RGX-111 for MPS diseases: Rockville, Maryland Wednesday, January 15, 2025, 12:00 H ...

Regenxbio, a prolific developer of gene therapy technology, will hand Japan’s Nippon ... The other treatment, RGX-111, treats ...